A Phase 3 interventional study of Rabeprazole ER and Ranitidine in Gastroesophageal Reflux Disease (GERD), sponsored by Eisai Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 27th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
13 studies in Gastroesophageal Reflux by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 13 finished, 12 (92%) have results posted.
Among the 13 studies in Gastroesophageal Reflux by Eisai Co., Ltd., this one is the 8th largest by enrollment, is one of 6 that started in 2008, is one of 9 in phase 3, and was the 9th registered.
Eisai Co., Ltd.’s Gastroesophageal Reflux studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 13 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, rabeprazole extended release 50 mg (once daily) or ranitidine 150 mg (twice daily).
Please note that this study is not a duplicate of E3810-G000-305; this is a separate study being conducted along with -305.
KEY INCLUSION CRITERIA:
1. Prior completion of Study E3810-G000-302 or -303. Subjects will need to have healed erosive esophagitis (absence of esophageal mucosal breaks or erosions) confirmed by EGD and sustained resolution of heartburn at Visit 4 or 5 of Study E3810-G000-302 or -303.
KEY EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rabeprazole ER
Drug: Ranitidine
50 mg capsule, taken orally, once daily for 26 weeks.
Also known as: Aciphex
150 mg capsule, taken orally, twice daily for 26 weeks.
Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
Time frame: Baseline to Week 26
Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities).
Time frame: Baseline to Week 26
Participants were eligible for this study if they had completed one of the healing studies (E3810-G000-302 or E3810-G000-303), had no evidence of oesophageal erosions, had sustained heartburn resolution, and had no record of any serious adverse event (SAE) related to study medication during the healing study.
| Milestone | RAN 150mg BID | RAB ER 50mg QD |
|---|---|---|
| Started | 60 | 177 |
| Completed | 35 | 134 |
| Not completed | 25 | 43 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Lost to follow-up | 6 | 9 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Other | 6 | 18 |
Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities).
| Percentage of Participants | RAN 150mg BID | RAB ER 50mg QD |
|---|---|---|
| Yes | 8.3 | 53.7 |
| No | 16.7 | 17.5 |
| Missing | 75 | 28.8 |
eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
| Percentage of Participants | RAN 150mg BID | RAB ER 50mg QD |
|---|---|---|
| Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 | 31.7 | 88.4 |
Collected over For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RAN 150mg BID | — | 1/56 (1.8%) | 22/56 (39.3%) |
| RAB ER 50mg QD | — | 3/170 (1.8%) | 42/170 (24.7%) |
| Event | RAN 150mg BID | RAB ER 50mg QD |
|---|---|---|
| PancreatitisGastrointestinal disorders | 1/56 | 0/170 |
| Chest painGeneral disorders | 0/56 | 1/170 |
| GastroenteritisInfections and infestations | 0/56 | 1/170 |
| PneumoniaInfections and infestations | 0/56 | 1/170 |
| DehydrationMetabolism and nutrition disorders | 0/56 | 1/170 |
| Event | RAN 150mg BID | RAB ER 50mg QD |
|---|---|---|
| Hiatus herniaGastrointestinal disorders | 6/56 | 7/170 |
| GastritisGastrointestinal disorders | 4/56 | 17/170 |
| Erosive oesophagitisGastrointestinal disorders | 5/56 | 2/170 |
| SinusitisInfections and infestations | 1/56 | 10/170 |
| DyspepsiaGastrointestinal disorders | 3/56 | 4/170 |
| Acquired oesophageal webGastrointestinal disorders | 3/56 | 2/170 |
| Age, Customized(Years) | RAN 150mg BID | RAB ER 50mg QD | Total |
|---|---|---|---|
| Mean | 47.5 ± 13.55 | 47.5 ± 12.06 | 47.5 ± 12.43 |
| Sex: Female, Male(Participants) | RAN 150mg BID | RAB ER 50mg QD | Total |
|---|---|---|---|
| Female | 28 | 88 | 116 |
| Male | 32 | 89 | 121 |
The record gives a start of Aug 2008, a primary completion of Aug 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole